A Retrospective Study to Evaluate the Clinical-Biologic Characteristics and Outcome of Patients Treated in Italy According to the Ibrutinib-Named Patient Program for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Phase of Trial: Phase IV
Latest Information Update: 21 Feb 2017
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 16 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 16 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 10 Aug 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2016.